Patents
Purified populations of stem cells
Patent Number: 6852533This is a powerful patent that covers essentially the endothelial precursor cell. The importance of endothelial precursors is their ability to induce angiogenesis. The patent has claims on any CD34 + VEGF R+ cell, as well as CD133+, VEGF R+ endothelial stem cell. Sources of these cells covered in the claims include circulating blood, cord blood, mobilized blood, and bone marrow. The...
Inventors: Rafii, Shahin (Great Neck, NY); Witte, Larry (Stormville, NY); Moore, Malcolm A. S. (New York, NY)
Assignee: Cornell Research Foundation, Inc. (Ithaca, NY); Sloan-Kettering Institute for Cancer Research (New York, NY); ImClone System Incorporated (New York, NY)
Date of First Priority Issue: Friday January 23rd, 1998
Method of isolating human neuroepithelial precursor cells from human fetal tissue
Patent Number: 6852532This patent teaches methods of extracting and purifying neuroepithelial precursor cells that can differentiate into a variety of neurological tissue and be useful for regenerative medicine. The patent essentially teaches to deplete cells expressing the markers A2B5, NG2 and eNCAM, so that approximately half of the purified cells are positive for AC133/2. The cells are extracted at the time...
Inventors: Mayer-Proschel, Margot (Pittsford, NY); Rao, Mahendra S. (Salt Lake City, UT); Tresco, Patrick A. (Sandy, UT); Messina, Darin J. (Salt Lake City, UT)
Assignee: University of Utah Research Foundation (Salt Lake City, UT)
Date of First Priority Issue: Thursday March 1st, 2001
Lectin-derived progenitor cell preservation factor and methods of use
Patent Number: 6852321This patent teaches that certain lectins (sugar binding proteins) may be used for the preservation of progenitor cells and stem cells. It is not clear which property of the lectins is involved in the preservation. The concept that lectins may be used in stem cell preservation brings to mind old experiments in which the preferentially affinity of lectins to cancer cell membranes was reported...
Inventors: Colucci, M. Gabriella (Dugenta, IT); Chrispeels, Maarten J. (La Jolla, CA); Moore, Jeffrey G. (Kennebunkport, ME)
Assignee: ImClone Systems Incorporated (New York, NY); Regents of the University of California (La Jolla, CA)
Date of First Priority Issue: Tuesday June 24th, 1997
Method of stimulating growth of melanocyte cells by administering stem cell factor
Patent Number: 6852313Melanocyte proliferation may be desired in a variety of pathological conditions. Melanocytes are important, for example in burn patients where it is desireble to obtain a sufficient layer of skin so as to avoid scepticemia. Melanocytic proliferation is demonstrated in this patent by treatment with stem cell factor (kit-ligand), as well as combinations of stem cell factor with other cytokines.
Inventors: Zsebo, Krisztina M. (Thousand Oaks, CA); Bosselman, Robert A. (Thousand Oaks, CA); Suggs, Sidney V. (Newbury Park, CA); Martin, Francis H. (Thousand Oaks, CA)
Assignee: Amgen Inc. (Thousand Oaks, CA)
Date of First Priority Issue: Friday October 16th, 1998
Production of tyrosine hydroxylase positive neurons
Patent Number: 6844312Neurons that express tyrosine hydroxylase (TH) are subfunctional in diseases such as Alzheimer's and Parkinson's. This patent teachs how to generate TH expressing neurons through contacting stem cells with FGF-1, an agent that activates protein kinase A, as well as a phorbol ester and dopamine. The ability to generate TH neurons in this manner may lead not only to in vitro generation...
Inventors: Weiss, Samuel (Calgary, CA); Shingo, Tetsuro (Okayama, JP)
Assignee: Stem Cell Therapeutics Inc. (Calgary, CA)
Date of First Priority Issue: Wednesday April 11th, 2001
Transforming growth factor beta (TGF-.beta.) blocking agent-treated stem cell composition and method
Patent Number: 6841542This patent claims ex vivo inhibition of TGF beta in hematopoietic stem cells in order to increase speed of engraftment post recipient marrow ablation. Since TGF beta is an endogenous inhibitor of stem cell proliferation, the inhibition of the inhibitor should lead to enhanced proliferation. The technology described in this patent would definately benefit from RNA...
Inventors: Bartelmez, Stephen H. (Seattle, WA); Iversen, Patrick L. (Corvallis, OR)
Assignee: AVI BioPharma, Inc. (Corvallis, OR)
Date of First Priority Issue: Thursday July 6th, 2000
Methods and use of motoneuronotrophic factors
Patent Number: 6841531This is a composition of matter patent on some endogenous factors that stimulate repair and regeneration of motor neurons. The authors have demonstrated some significant biological activities of the "motoneuronotrophic" factors in nerve injury, including ability to accelerating healing after cutting of the sciatic nerve in rats.
Inventor: Chau, Raymond Ming Wah (Hong Kong, HK)
Assignee: Genervon Biopharmaceuticals LLC (Montebello, CA)
Date of First Priority Issue: Friday September 27th, 1996
Modulation of primary stem cell differentiation using an insulin-like growth factor binding protein
Patent Number: 6841386Insulin like growth factor (IGF) is involved in numerous biological activities. The basis of this patent is that IGF possesses some differentiation inducing activity for CD34+ CD38- hematopoietic stem cells. The ability of stem cells to be expanded ex vivo depends on not allowing said cells to differentiate. This patent teaches that blocking IGF signalling can inhibit hematopoietic stem...
Inventors: Kraus, Morey (Jefferson, MA); Deng, Hongkui (Framingham, MA); Liu, Liqin (Framingham, MA)
Assignee: Viacell, Inc. (Worcester, MA)
Date of First Priority Issue: Tuesday April 10th, 2001
Use of adipose tissue-derived stromal cells for chondrocyte differentiation and cartilage repair
Patent Number: 6841150This appears to be a very important patent in that it teaches the use of adipose stem cells for generating chondrocytes and using the chondrocytes to heal cartilage. This patent should be compared to ones by Osiris that use adipose derived mesenchymal stem cells for cartilage repair, as well as by Cytori which uses adipose derived stem cells for a variety of indications.
Inventors: Halvorsen, Yuan-Di C. (Holly Springs, NC); Wilkison, William O. (Bahama, NC); Gimble, Jeffrey Martin (Chapel Hill, NC)
Assignee: Artecal, Sciences, Inc. (Durham, NC)
Date of First Priority Issue: Thursday August 19th, 1999
Stem cell factor compositions
Patent Number: 6841147This is a composition of matter patent on the kit-ligand, otherwise known as stem cell factor. Stem cell factor is involved in regulation of a variety of stem cells in addition to hematopoietic stem cells. This patent is particularly important for when novel methods of inducing stem cell differentation in vivo are discovered and stem cell factor may be added to these methods to either induce...
Inventors: Zsebo, Krisztina M. (Thousand Oaks, CA); Bosselman, Robert A. (Thousand Oaks, CA); Suggs, Sidney V. (Newbury Park, CA); Martin, Francis H. (Thousand Oaks, CA)
Assignee: Amgen, Inc. (Thousand Oaks, CA)
Date of First Priority Issue: Monday October 16th, 1989